INS and type 2 diabetes mellitus: SURPASS-3 (ClinicalTrials.gov identifier: NCT03882970): assesses efficacy and safety of tirzepatide versus insulin degludec in patients with T2D prescribed metformin with or without SGLT2 inhibitors.72